雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Eosinophilic Gastrointestinal Disorders; Classification and Current Trend Norihisa ISHIMURA 1 1Department of Internal Medicine II, Shimane University Faculty of Medicine, Shimane, Japan Keyword: eosinophilic gastrointestinal disease , eosinophilic esophagitis , eosinophilic gastroenteritis , epidemiology pp.1328-1335
Published Date 2022/8/25
DOI https://doi.org/10.24479/endo.0000000282
  • Abstract
  • Look Inside
  • Reference
  • Cited by

 Eosinophilic gastrointestinal disorders (EGID) are chronic inflammatory disorders of the GI tract with pathologic eosinophilic infiltration in the absence of secondary causes, and are designated as intractable diseases in Japan. T helper 2 (Th2) immune responses related to food and/or aeroallergens may play a central role in dysfunctional eosinophilic inflammation in the GI tract. Depending on the involved GI tract, EGID are divided into eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EGE or non-EoE EGID). Over the past two decades, both incidence and prevalence of EoE have been rapidly increasing worldwide, and international consensus guidelines have been developed based on the increasing amount of knowledge on EoE. For non-EoE EGID, nomenclature of the diseases, diagnostic criteria, and treatment strategies have not been internationally unified yet. Last year, an international consensus on-line meeting regarding nomenclature of EGID with the participation of 91 experts was held. This international consensus process has resulted in updated EGID nomenclature that should be used for both clinical and research purposes. EGID will be the umbrella term for diseases of eosinophilic infiltration of the GI tract; the term “eosinophilic gastroenteritis (EGE)” will no longer be used in this role, and will ideally be replaced in favor of more specific naming conventions, such as eosinophilic gastritis (EoG). It is expected that research progress regarding the pathogenic difference between EoE and non-EoE EGID, as well as treatment strategies including biologic agents for non-EoE EGID will advance more rapidly.


© tokyo-igakusha.co.jp. All right reserved.

基本情報

電子版ISSN 印刷版ISSN 0915-3217 東京医学社

関連文献

もっと見る

文献を共有